Clinical Trials Directory

Trials / Conditions / EGFR L858R

EGFR L858R

6 registered clinical trials studyying EGFR L858R — 2 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingAn Open-Label, Single-Arm, Dose-Escalation Phase I Study Evaluating the Safety, Tolerability, and Preliminary
NCT07461727
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1
RecruitingA Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib i
NCT06053099
Intergroupe Francophone de Cancerologie ThoraciqueN/A
Active Not RecruitingHERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally
NCT05338970
Daiichi SankyoPhase 3
CompletedBevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation
NCT05263947
Tianjin Medical University Cancer Institute and HospitalPhase 2
Terminated(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC
NCT05153408
Blueprint Medicines CorporationPhase 1
Terminated(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC
NCT04862780
Blueprint Medicines CorporationPhase 1